In conclusion, our data demonstrate that while CD24 is distinctively but diversely expressed during tumor development in genetic models of breast and prostate cancer, lack of CD24 did not significantly influence tumor initiation and only partly affected tumor burden in these models. This evidence concerns the gene CD24 and prostate cancer.